Ryan Watkins, Ana Gamo, Seung Hyuk Choi, Manoj Kumar, EeeLN Buckarma, Chantal McCabe, Jennifer Tomlinson, David Pereya, Blaz Lupse, Shirin Geravandi, Nathan W Werneburg, Chen Wang, Patrick Starlinger, Siying Zhu, Sijia Li, Shan Yu, Murali Surakattula, Tyler Baguley, Amin Ardestani, Kathrin Maedler, Jason Roland, Van Nguyen-Tran, Sean Joseph, Mike Petrassi, Nikki Rogers, Gregory Gores, Arnab Chatterjee, Matthew Tremblay, Weijun Shen, Rory Smoot
Dysfunctional liver regeneration following surgical resection remains a major cause of postoperative mortality and has no therapeutic options. Without targeted therapies, the current treatment paradigm relies on supportive therapy until homeostasis can be achieved. Pharmacologic acceleration of regeneration represents an alternative therapeutic avenue. Therefore, we aimed to generate a small molecule inhibitor that could accelerate liver regeneration with an emphasis on diseased models, which represent a significant portion of patients who require surgical resection and are often not studied...
March 2024: PNAS Nexus